GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » Cyclically Adjusted PB Ratio

RIGL (Rigel Pharmaceuticals) Cyclically Adjusted PB Ratio : 4.20 (As of May. 27, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-27), Rigel Pharmaceuticals's current share price is $19.62. Rigel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $4.67. Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 4.20.

The historical rank and industry rank for Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

RIGL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.52   Med: 1.31   Max: 5.04
Current: 4.06

During the past years, Rigel Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 5.04. The lowest was 0.52. And the median was 1.31.

RIGL's Cyclically Adjusted PB Ratio is ranked worse than
76.83% of 669 companies
in the Biotechnology industry
Industry Median: 1.48 vs RIGL: 4.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was $1.039. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.67 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rigel Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Rigel Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 1.96 1.41 1.99 3.36

Rigel Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 1.36 2.95 3.36 3.86

Competitive Comparison of Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Rigel Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=19.62/4.67
=4.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Rigel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.039/134.9266*134.9266
=1.039

Current CPI (Mar. 2025) = 134.9266.

Rigel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 11.429 100.684 15.316
201509 10.890 100.392 14.636
201512 10.092 99.792 13.645
201603 8.332 100.470 11.189
201606 7.794 101.688 10.342
201609 6.665 101.861 8.829
201612 5.543 101.863 7.342
201703 6.868 102.862 9.009
201706 5.621 103.349 7.338
201709 3.868 104.136 5.012
201712 6.856 104.011 8.894
201803 5.415 105.290 6.939
201806 7.424 106.317 9.422
201809 6.209 106.507 7.866
201812 6.573 105.998 8.367
201903 5.701 107.251 7.172
201906 4.671 108.070 5.832
201909 4.111 108.329 5.120
201912 3.203 108.420 3.986
202003 4.657 108.902 5.770
202006 3.742 108.767 4.642
202009 3.016 109.815 3.706
202012 2.010 109.897 2.468
202103 4.602 111.754 5.556
202106 3.987 114.631 4.693
202109 2.905 115.734 3.387
202112 1.770 117.630 2.030
202203 0.395 121.301 0.439
202206 -0.213 125.017 -0.230
202209 -1.148 125.227 -1.237
202212 -0.785 125.222 -0.846
202303 -1.397 127.348 -1.480
202306 -1.612 128.729 -1.690
202309 -1.826 129.860 -1.897
202312 -1.638 129.419 -1.708
202403 -1.806 131.776 -1.849
202406 -1.700 132.554 -1.730
202409 -0.831 133.029 -0.843
202412 0.186 133.157 0.188
202503 1.039 134.927 1.039

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rigel Pharmaceuticals  (NAS:RIGL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rigel Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Executives
Raymond J. Furey officer: EVP, GC & Corp Sec 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
David A Santos officer: EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Dean L Schorno officer: EVP & Chief Financial Officer 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raul R Rodriguez officer: Sr VP of Bus Dev and Com Ops 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer officer: EVP & CMO 5491 OPTICAL CT., SAN JOSE CA 95138
Alison L. Hannah director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan officer: Principal Accounting Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii officer: EVP & Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel officer: EVP Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080